Helping women navigate risk-reducing mastectomy decisions

For Australian women carrying a BRCA1, BRCA2, or other high-risk gene variant, the conversation about risk-reducing mastectomy is rarely simple. It sits at the intersection of genetic information, surgical options, body image, family planning, and long-term surveillance. Clinicians across Queensland have noticed that women often arrive at appointments with a bundle of online printouts, well-meaning advice from relatives, and unanswered questions about what life looks like after surgery. The development of a dedicated decision aid aims to bring clarity, structure, and shared meaning to that conversation.

The work sits within a broader push to translate research into routine clinical care, so that women facing these choices are guided by evidence that reflects Australian populations, health system pathways, and cultural contexts. Rather than replacing clinical judgement, a decision aid acts as a structured companion, helping women weigh values, clarify preferences, and prepare for consultations with surgeons, genetic counsellors, and breast care nurses.

Why a decision aid is needed

The numbers tell part of the story. Breast cancer remains the most commonly diagnosed cancer among Australian women, with Cancer Council Australia reporting roughly 20,000 new cases each year. A smaller but clinically significant group of women face a much higher lifetime risk because of inherited mutations, and for them, prophylactic mastectomy can reduce the chance of developing breast cancer by 90 percent or more. Yet uptake varies widely, and surveys consistently show that women feel under-informed about the trade-offs, particularly around reconstruction timing, breastfeeding intentions, and ongoing screening of remaining tissue.

The decision is also time-sensitive. Many women meet with a genetic counsellor shortly after receiving a positive result, then see a breast surgeon weeks or months later. In that gap, anxiety can rise, and misinformation fills the void. A structured aid is intended to bridge that interval with reliable, locally relevant information, so that the first surgical consultation is a true shared decision rather than a rushed confirmation of an already-made choice.

What goes into the decision aid

A useful decision aid is more than a pamphlet. The project team is drawing on evidence summaries about surgical techniques, recovery timelines, complication rates, and the difference between immediate and delayed reconstruction. It includes visual diagrams of anatomical outcomes, plain-English explanations of terms like nipple-sparing mastectomy, and honest descriptions of sensory changes, scarring, and the small but real risk of chronic pain.

Alongside clinical facts, the tool incorporates values clarification exercises. Women are invited to consider how they feel about ongoing MRI surveillance, the impact on intimacy, and the possibility of future pregnancies. These are not abstract questions for a 32-year-old woman in Brisbane who is still planning a family, nor for a 58-year-old in regional Queensland who has already finished childbearing. The aid is designed to reflect that diversity, with adjustable reading levels and optional modules for partners or adult daughters who attend appointments.

Patient voices and co-design

Nothing about a decision aid works without consumer input. From the outset, the research team partnered with women who have already undergone the procedure, as well as women currently weighing the choice. Focus groups in Brisbane, Townsville, and Cairns revealed important nuances: Aboriginal and Torres Strait Islander women spoke about the need for yarning-based conversation rather than written checklists, while women from Mandarin and Vietnamese backgrounds asked for translated summaries and clear explanations of how Medicare covers genetic testing and surgery.

The co-design process also surfaced an unexpected insight. Many women wanted a physical take-home resource they could reread, share with family, and return to during sleepless nights. Digital tools help, but paper still matters, particularly in rural communities with patchy internet. Community organisations have a role here too, from suburban libraries to regional resource hubs. Some local centres, such as Friends of the Library, have experimented with health information displays, offering a model that Australian community groups could adapt for hereditary cancer resources.

Clinical integration in the Australian context

A decision aid only matters if it reaches the people who need it. The project is being mapped onto existing clinical pathways, from familial cancer clinics at the Royal Brisbane and Women's Hospital to outreach services run by BreastScreen Australia and the genetic counselling teams attached to public hospitals. The aim is for the resource to be introduced early, ideally at the point of genetic result disclosure, and then carried forward into surgical consultations.

Integration also means thinking about funding and access. Surgery for risk-reducing mastectomy is covered under Medicare when clinical criteria are met, and reconstruction is rebated through both Medicare and private insurers, though out-of-pocket costs vary. The decision aid clearly explains these arrangements, so women do not assume the procedure is unaffordable and therefore rule it out before discussing it with a clinician. General practitioners are also given a short guide on how to raise the topic during routine appointments, which is often the first time a woman hears that such an option exists. The wider research translation work happening across Brisbane Diamantina provides a useful framework for embedding the tool into routine practice.

Measuring impact and next steps

Evaluation is built into the project from day one. The team will track whether the aid improves knowledge scores, reduces decisional conflict, and influences the timing and quality of consultations. Qualitative interviews with women and clinicians will capture the human side, including whether the tool helped family members understand the decision or made the surgery feel less isolating.

Looking ahead, the plan is to refine the aid based on pilot feedback, secure ethics approval for broader rollout, and eventually make it freely available through public hospital libraries, cancer councils, and online portals. The researchers are also keen to link the work with related projects, such as this genetics collaboration guide on rare disease diagnostics, so that women with uncommon variants are not left without support. The long-term hope is simple: that every Australian woman facing this choice feels heard, informed, and confident that the path she chooses reflects her own values, not a gap in the system.

If you or someone you know is considering risk-reducing surgery, speak with your GP or a familial cancer clinic, ask about genetic counselling, and request a copy of the decision aid once it is available in your service. Conversations like these are easier when the right information is at hand.